{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"ss-31-glp-1","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-glp-1/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/ss-31-glp-1/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-glp-1/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-glp-1/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-glp-1/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/ss-31-glp-1/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/ss-31-glp-1/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"ss-31-glp-1","title":"SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:42:03.325Z","body_excerpt":"## What's breaking down\n\nMitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.\n\nSS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.\n\n1. GLP-1 driven weight loss alters energy demand and substrate use.\n2. Mitochondria in muscle and other tissues may experience increased oxidative load during this transition.\n3. SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin.\n4. Preclinical models show this association correlates with improved ATP production and reduced electron leak.\n5. Therefore, if mitochondrial efficiency is a limiting factor for you during GLP-1 therapy, the peptide is studied for direct membrane stabilization rather than downstream metabolic signaling.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists primarily support metabolism by enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying. This produces sustained caloric deficit and weight reduction. The weight loss itself lowers mechanical load on the musculoskeletal system—approximately 4 lb of lumbar compressive force per pound lost. However, rapid loss can trade off against lean mass preservation if resistance training and protein are insufficient. The drug class does not directly address mitochondrial membrane integrity; any mitochondrial benefit would be indirect through reduced adiposity and improved glycemic control.\n\n## How these fit together\n\nSS-31 addresses the mitochondrial membrane layer. GLP-1 agonists address systemic energy balance and mechanical unloading. In a single-compound focus on SS-31, the two are considered together because mitochondrial repair pathways may complement the metabolic unloading that occurs with GLP-1 use, without overlapping mechanisms.\n\n## What the evidence actually shows\n\nHuman trial data for SS-31 exists in primary mitochondrial myopathy and heart failure populations. One randomized, placebo-controlled trial in adults with primary mitochondrial myopathy reported a dose-dependent increase in 6-minute walk test distance after 5 days of intravenous dosing (Class I evidence for short-term exercise performance). A phase 3 trial (MMPOWER-3) showed mixed genotype-specific results. In heart failure, a 28-day subcutaneous study found the compound well tolerated but did not meet primary efficacy endpoints in all measures.\n\nPreclinical studies (rodent and cell models) consistently demonstrate cardiolipin binding, improved mitochondrial respiration, and reduced ROS. No published human trials examine SS-31 combined with GLP-1 agonists. Evidence inventory: multiple human trials (phase 2/3) for mitochondrial disease indications; dozens of animal studies on mitochondrial function; limited anecdotal reports of concurrent use with GLP-1 compounds on forums.\n\n## What scientists say\n\nResearchers describe SS-31 as selectively localizing to mitochondria and stabilizing cardiolipin to support electron transport chain supercomplexes. Clinical trial summaries note good short-t","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c4","text":"No published human trials examine concurrent SS-31 and GLP-1 agonist use.","tier":"human","weight":0.8,"section":"What we do not know","slot":null,"interaction_risk":false,"status":"active","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gap for the specific cross.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c1","text":"SS-31 binds cardiolipin in the inner mitochondrial membrane and is associated with improved electron transport efficiency in preclinical models.","tier":"preclinical","weight":0.5,"section":"Why SS-31 (Elamipretide) might help you","slot":null,"interaction_risk":false,"status":"active","source_ids":["s14"],"source_status":"sourced","why_material":"Establishes core mechanism discussed for mitochondrial repair layer.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c3","text":"GLP-1 agonists produce weight loss that mechanically unloads the spine and joints by approximately 4 lb compressive force per pound lost.","tier":"mechanistic","weight":0.3,"section":"Why GLP-1 agonists (class) matters for you","slot":null,"interaction_risk":false,"status":"active","source_ids":[],"source_status":"unsourced","why_material":"Standard biomechanical relationship used to frame load reduction benefit.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c2","text":"A randomized placebo-controlled trial in primary mitochondrial myopathy patients showed dose-dependent improvement in 6-minute walk distance after 5 days of IV SS-31 (Class I evidence).","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s5"],"source_status":"sourced","why_material":"Direct human efficacy signal for exercise performance.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c5","text":"FDA granted accelerated approval to elamipretide (SS-31) for Barth syndrome in 2025 based on TAZPOWER trial data.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s19"],"source_status":"sourced","why_material":"Current regulatory status as of 2026.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c6","text":"Reddit users report subjective energy or fatigue changes when using SS-31 alongside tirzepatide; reports are anecdotal and mixed.","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["s10"],"source_status":"sourced","why_material":"Documents real-world discussion of the combination.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/","title":"Mitochondrial protein interaction landscape of SS-31","quote":"The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown.","summary":"Identifies SS-31 interactors linked to ATP production and 2-oxoglutarate metabolism.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"942b2c42e49f0f647400e1758e9acab4cf4ac56269bb1610b02a376e5e02936b"},{"id":"s5","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Participants who received the highest dose of elamipretide walked a mean of 64.5 m farther at day 5 compared to a change of 20.4 m in the placebo group (p = 0.053).","summary":"Class I evidence for short-term exercise improvement in PMM patients.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"2315a846a52abfcf91034b65a4cb87902cf2ef102f30f59243e6c642b67ccc7d"},{"id":"s19","type":"news","url":"https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/","title":"FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31","quote":"The recent FDA approval of elamipretide is for the treatment of a rare disease...","summary":"Reports 2025 FDA approval for Barth syndrome.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"8ad2641afe4c0f0ca27e85a3dfb7a77b5e07efdd00d8d1f182996b2a59b9e978"},{"id":"s10","type":"reddit","url":"https://www.reddit.com/r/compoundedtirzepatide/comments/1scbh7n/anyone_here_taking_other_peptides_along_with/","title":"Anyone here taking other peptides along with tirzepatide?","quote":"I do feel like I get a little energy boost from the 5Amino/ ss-31...","summary":"Anecdotal report of SS-31 with tirzepatide.","claim_ids":["c6"],"link_status":"ok","quote_status":"unverified","hash":"a25b289ab77277297d3eecf0fac62c4eeaa3908ad5aa06572b7150444f6b27ab"}],"anecdotal_sources":[{"id":"s10","type":"reddit","url":"https://www.reddit.com/r/compoundedtirzepatide/comments/1scbh7n/anyone_here_taking_other_peptides_along_with/","title":"Anyone here taking other peptides along with tirzepatide?","quote":"I do feel like I get a little energy boost from the 5Amino/ ss-31...","summary":"Anecdotal report of SS-31 with tirzepatide.","claim_ids":["c6"],"link_status":"ok","quote_status":"unverified","hash":"a25b289ab77277297d3eecf0fac62c4eeaa3908ad5aa06572b7150444f6b27ab"}],"scientific_sources":[{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/","title":"Mitochondrial protein interaction landscape of SS-31","quote":"The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown.","summary":"Identifies SS-31 interactors linked to ATP production and 2-oxoglutarate metabolism.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"942b2c42e49f0f647400e1758e9acab4cf4ac56269bb1610b02a376e5e02936b"},{"id":"s5","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Participants who received the highest dose of elamipretide walked a mean of 64.5 m farther at day 5 compared to a change of 20.4 m in the placebo group (p = 0.053).","summary":"Class I evidence for short-term exercise improvement in PMM patients.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"2315a846a52abfcf91034b65a4cb87902cf2ef102f30f59243e6c642b67ccc7d"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"ss-31-glp-1","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":6,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":6,"claims_total":6,"sources":4,"anecdotal":1,"scientific":2,"user_reports":0,"questions":0,"evidence_ingests":0}}